BioPharmSignal logoBioPharmSignal

Biotech News

ANI Pharmaceuticals to Present at Upcoming November Investor Conferences

ANI Pharmaceuticals (ANIP)ANI PharmaceuticalsCompany update

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in presentations and fireside chats at the following upcoming investor conferences:

Related news

ANIPANI Pharmaceuticals2026-02-24 11:50 EST

ANI Pharmaceuticals to Present at Upcoming Investor Conferences

ANIPANI Pharmaceuticals2026-09-03 10:55 EST

ANI Pharmaceuticals to Present at September Investor Conferences

ALVOAlvotech2026-11-02 12:00 EST

Alvotech to Present at Upcoming Investor Conferences in November

ALVOAlvotech2026-08-27 12:00 EST

Alvotech to present at upcoming investor conferences in September

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

CHRSCoherus BioSciences, Inc.2026-02-23 14:30 EST

Coherus Oncology to Participate in Upcoming Investor Conferences

AMRXAmneal Pharmaceuticals2026-03-05 21:05 EST

Amneal to Participate in Upcoming Investor Conference

AMRXAmneal Pharmaceuticals2026-10-08 12:00 EST

Amneal to Report Third Quarter 2026 Results on November 3, 2026

View all latest news

ANI Pharmaceuticals

Rare-Disease and Specialty Pharmaceuticals ANI Pharmaceuticals develops and commercializes medicines across rare disease, ophthalmology and established pharmaceutical markets. Its model combines branded specialty products with a portfolio of generic medicines. Cortrophin Gel Purified Cortrophin Gel is an adrenocorticotropic hormone...

Recent company news

ANIPANI Pharmaceuticals2026-11-05 11:51 EST

ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results

ANIPANI Pharmaceuticals2026-11-05 11:50 EST

REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

ANIPANI Pharmaceuticals2026-11-05 06:33 EST

ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

ANIPANI Pharmaceuticals2026-11-03 11:55 EST

ANI Pharmaceuticals to Present at Upcoming November Investor Conferences

ANIPANI Pharmaceuticals2026-10-23 10:55 EST

ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

Stock data

Close
69.62 USD
Market cap
1.7B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States